In a report released today, Serge Belanger from Needham maintained a Buy rating on Viridian Therapeutics (VRDN – Research Report), with a price target of $38.00.
Serge Belanger has given his Buy rating due to a combination of factors that highlight Viridian Therapeutics’ promising position in the market. One of the key reasons is the company’s strategic advancements in its clinical programs, particularly the anticipated long-term efficacy data from the THRIVE and THRIVE-2 trials. These trials are expected to provide insights into the durability of the treatment regimen, which is crucial for positioning the company as a leader in the TED therapy market.
Additionally, the competitive landscape has shifted in favor of Viridian Therapeutics, as recent setbacks faced by competitors like Acelyrin and Sling Therapeutics have positioned VRDN advantageously. This, combined with the company’s robust pipeline and strategic focus, supports the Buy rating and the price target of $38, indicating confidence in the company’s future growth potential and market leadership.
According to TipRanks, Belanger is a 2-star analyst with an average return of 0.4% and a 40.64% success rate. Belanger covers the Healthcare sector, focusing on stocks such as Revance Therapeutics, Viridian Therapeutics, and Trevi Therapeutics.
In another report released today, Wedbush also maintained a Buy rating on the stock with a $46.00 price target.